Lesoil, Constance
Bombois, Stéphanie
Guinebretiere, Octave
Houot, Marion
Bahrami, Mahsa
Levy, Marcel
Genthon, Rémy
Bozon, Frédérique
Jean-Marie, Heidy
Epelbaum, Stéphane
Foulon, Pierre
Villain, Nicolas
Dubois, Bruno
Article History
Received: 5 December 2022
Accepted: 11 March 2023
First Online: 3 April 2023
Declarations
:
: All participants gave written informed consent. The study was approved by the Ethical Committee (Comité de Protection des Personnes (CPP) du Sud-Ouest et Outre-Mer 4) (AM2020-277/02/CPP2019-10–077).
: Not applicable.
: SB received honoraria from Biogen for a symposium and from Esai for a lecture, and is investigator without personal fees in therapeutical trials from Biogen, Roche, Eisai, Eli Lilly, Janssen, Johnson & Johnson, Alector, UCB, NovoNordisk. SE received lecture honoraria from Roche and consultant honoraria for participating in scientific advisory boards of GE Healthcare, Astellas Pharma, Roche, Biogen and Eli Lilly. NV reports grants from Fondation Recherche Alzheimer, Département Médical Universitaire APHP–Sorbonne Université, and non-financial support from GE Healthcare, Merz Pharma, UCB Pharma, Medtronic, and Laboratoire Aguettant, outside the submitted work. BD reports personal fees from Biogen, ABScience, and grants paid to his institution from Roche, Merck-Avenir Foundation, and Fondation Recherche sur Alzheimer, outside the submitted work.Pierre Foulon is Director and Heïdy Jean-Marie is Technical Director of Mindmaze France, a private company that develops DTx solutions.